AbbVie Inc. is 92.1x more valuable than Erasca, Inc. by market capitalization ($402.35 B vs $4.37 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ERAS | ABBV |
|---|---|---|
| Market cap | $4.37 B | $402.35 B |
| US-listed rank | #1516 | #31 |
| Revenue (latest FY) | - | $61.16B |
| Net income (latest FY) | -$124.55M | $4.23B |
| Net margin | - | 6.9% |
| P/E (trailing FY) | - | 95.2 |
| SEC filings | 326 | 1,008 |
AbbVie Inc. is 92.1x more valuable than Erasca, Inc. by market capitalization ($402.35 B vs $4.37 B).
Full pages: Erasca, Inc. and AbbVie Inc., or browse the full rankings.